by Corat | Oct 12, 2021
Clinical Trials Text/English Text/Deutsch Informationen für Patienten Clinical Study In order to gain information about the risks and the effectiveness of our therapeutic COVID-19 antibodies, we conduct clinical trials. Currently, our lead candidate COR-101 is...
by Corat | Oct 8, 2021
News & Events News / press releases Categories All 2020 2021 2022 Events News Reset TV report on COR-101 May 11, 2021 CORAT’s CEO Dr. Andreas Herrmann and CSO Dr. André Frenzel comment in international television on the start of clinical studies with...
by Corat | Oct 8, 2021
Partnering SARS-CoV-2 neutralizing antibodies CORAT always welcomes joint research projects and alliances to explore new avenues for the development of targeted SARS-CoV-2 therapies. COR-101 Program Corat is actively looking for strategic partners supporting us to...
by Corat | Oct 8, 2021
Technology Technology behind CORAT CORAT antibodies are generated by the Nobel-prize awarded molecular biology technique antibody phage display to isolate human monoclonal antibodies from blood that are indistinguishable from our own body antibodies – with one...
by Corat | Oct 8, 2021
History & Mission Corona Antibody Team CORAT Therapeutics GmbH is a clinical phase biopharmaceutical company dedicated to develop therapeutic products to fight SARS-CoV-2 mediated COVID-19. CORAT was founded as a spin off from the recombinant antibody development...
